Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies.

He DM, Ren BG, Liu S, Tan LZ, Cieply K, Tseng G, Yu YP, Luo JH.

Oncogene. 2017 Jun 22;36(25):3629-3639. doi: 10.1038/onc.2017.123. Epub 2017 May 8.

PMID:
28481876
2.

Hsp90 dependence of a kinase is determined by its conformational landscape.

Luo Q, Boczek EE, Wang Q, Buchner J, Kaila VR.

Sci Rep. 2017 Mar 14;7:43996. doi: 10.1038/srep43996.

3.

Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation.

Mitra S, Ghosh B, Gayen N, Roy J, Mandal AK.

J Biol Chem. 2016 Nov 18;291(47):24579-24593. Epub 2016 Oct 4.

PMID:
27703006
4.

New insights on the role of epigenetic alterations in hepatocellular carcinoma.

Frau M, Feo CF, Feo F, Pascale RM.

J Hepatocell Carcinoma. 2014 Jun 12;1:65-83. doi: 10.2147/JHC.S44506. eCollection 2014. Review.

5.

The co-chaperone Cdc37 regulates the rabies virus phosphoprotein stability by targeting to Hsp90AA1 machinery.

Xu Y, Liu F, Liu J, Wang D, Yan Y, Ji S, Zan J, Zhou J.

Sci Rep. 2016 Jun 2;6:27123. doi: 10.1038/srep27123.

6.

Hsp90 modulates the stability of MLKL and is required for TNF-induced necroptosis.

Zhao XM, Chen Z, Zhao JB, Zhang PP, Pu YF, Jiang SH, Hou JJ, Cui YM, Jia XL, Zhang SQ.

Cell Death Dis. 2016 Feb 11;7:e2089. doi: 10.1038/cddis.2015.390.

7.

Targeting CDK4 and CDK6: From Discovery to Therapy.

Sherr CJ, Beach D, Shapiro GI.

Cancer Discov. 2016 Apr;6(4):353-67. doi: 10.1158/2159-8290.CD-15-0894. Epub 2015 Dec 11. Review.

8.

Conformational processing of oncogenic v-Src kinase by the molecular chaperone Hsp90.

Boczek EE, Reefschläger LG, Dehling M, Struller TJ, Häusler E, Seidl A, Kaila VR, Buchner J.

Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):E3189-98. doi: 10.1073/pnas.1424342112. Epub 2015 Jun 8.

9.

Targeting Hsp90 in urothelial carcinoma.

Chehab M, Caza T, Skotnicki K, Landas S, Bratslavsky G, Mollapour M, Bourboulia D.

Oncotarget. 2015 Apr 20;6(11):8454-73. Review.

10.

Causes and consequences of protein folding stress in aneuploid cells.

Donnelly N, Storchová Z.

Cell Cycle. 2015;14(4):495-501. doi: 10.1080/15384101.2015.1006043.

11.

The cyclin D1-CDK4 oncogenic interactome enables identification of potential novel oncogenes and clinical prognosis.

Jirawatnotai S, Sharma S, Michowski W, Suktitipat B, Geng Y, Quackenbush J, Elias JE, Gygi SP, Wang YE, Sicinski P.

Cell Cycle. 2014;13(18):2889-900. doi: 10.4161/15384101.2014.946850.

12.

Regulation of Greatwall kinase by protein stabilization and nuclear localization.

Yamamoto TM, Wang L, Fisher LA, Eckerdt FD, Peng A.

Cell Cycle. 2014;13(22):3565-75. doi: 10.4161/15384101.2014.962942.

13.

Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease.

Blair LJ, Sabbagh JJ, Dickey CA.

Expert Opin Ther Targets. 2014 Oct;18(10):1219-32. doi: 10.1517/14728222.2014.943185. Epub 2014 Jul 29. Review.

14.

Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.

Chen Y, Chen J, Yu J, Yang G, Temple E, Harbinski F, Gao H, Wilson C, Pagliarini R, Zhou W.

J Biol Chem. 2014 Jul 4;289(27):18914-27. doi: 10.1074/jbc.M114.574053. Epub 2014 May 15.

15.

The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis.

Lou X, Zhang J, Liu S, Xu N, Liao DJ.

Cell Cycle. 2014;13(11):1677-93. doi: 10.4161/cc.29082. Epub 2014 May 5. Review.

16.

Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.

Ahmad S, Gupta S, Kumar R, Varshney GC, Raghava GP.

Sci Rep. 2014 Mar 27;4:4483. doi: 10.1038/srep04483.

17.

Designed Hsp90 heterodimers reveal an asymmetric ATPase-driven mechanism in vivo.

Mishra P, Bolon DN.

Mol Cell. 2014 Jan 23;53(2):344-50. doi: 10.1016/j.molcel.2013.12.024.

18.

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.

Smith JR, de Billy E, Hobbs S, Powers M, Prodromou C, Pearl L, Clarke PA, Workman P.

Oncogene. 2015 Jan 2;34(1):15-26. doi: 10.1038/onc.2013.519. Epub 2013 Dec 2.

19.
20.

Interaction of heat shock protein 90 and the co-chaperone Cpr6 with Ura2, a bifunctional enzyme required for pyrimidine biosynthesis.

Zuehlke AD, Wren N, Tenge V, Johnson JL.

J Biol Chem. 2013 Sep 20;288(38):27406-14. doi: 10.1074/jbc.M113.504142. Epub 2013 Aug 7.

Supplemental Content

Support Center